Unadjusted analysis of the effect of variables on 10-year overall survival (OS) and disease-free survival (DFS).
| Characteristics | OS No. (%) | P | DFS No. (%) | P |
|---|---|---|---|---|
| Age, years | 0.85 | 0.71 | ||
| < 50 | 252 (82) | 228 (74) | ||
| ≥ 50 | 191 (82) | 167 (72) | ||
| Tumor size (pT) | 0.29 | 0.11 | ||
| T1 | 152 (84) | 140 (77) | ||
| T2 | 291 (81) | 255 (71) | ||
| Tumor location | 0.52 | 0.30 | ||
| Medial | 102 (83) | 90 (73) | ||
| Central | 107 (86) | 98 (78) | ||
| Lateral | 234 (80) | 207 (71) | ||
| Histology | 0.52 | 0.18 | ||
| Ductal | 354 (82) | 312 (72) | ||
| Non-Ductal | 89 (84) | 83 (78) | ||
| Histological grade | 0.35 | 0.61 | ||
| Grade I | 223 (93) | 199 (83) | ||
| Grade II | 42 (80) | 41 (77) | ||
| Grade III | 178 (72) | 155 (63) | ||
| Number of positive nodes | < 0.001 | 0.001 | ||
| None | 303 (87) | 272 (78) | ||
| 1-3 nodes | 140 (73) | 123 (64) | ||
| Positive nodes (%) | < 0.001 | < 0.001 | ||
| ≤ 20% | 440 (83) | 393 (74) | ||
| > 20% | 3 (43) | 2 (29) | ||
| Estrogen receptor status | 0.68 | 0.80 | ||
| Positive | 161 (79) | 147 (72) | ||
| Negative | 146 (80) | 128 (70) | ||
| Progesterone receptor status | 0.26 | 0.42 | ||
| Positive | 166 (85) | 146 (75) | ||
| Negative | 154 (77) | 138 (69) | ||
| Preoperation chemotherapy | 0.28 | 0.67 | ||
| Yes | 92 (77) | 88 (74) | ||
| No | 351 (83) | 307 (73) | ||
| Postoperation chemotherapy | 0.04 | 0.39 | ||
| Yes | 418 (83) | 371 (74) | ||
| No | 25 (69) | 24 (67) | ||
| Cycles of postoperation chemotherapy | 0.056 | 0.11 | ||
| ≤ 4 | 296 (81) | 262 (72) | ||
| > 4 | 122 (88) | 109 (78) | ||
| Radiotherapy | 0.46 | 0.73 | ||
| Yes | 231 (84) | 204 (74) | ||
| No | 212 (80) | 191 (72) | ||
| Hormonal therapy | 0.56 | 0.62 | ||
| Yes | 198 (84) | 176 (75) | ||
| No | 245 (80) | 219 (72) |